<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="18368">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01969110</url>
  </required_header>
  <id_info>
    <org_study_id>AEPIPD</org_study_id>
    <nct_id>NCT01969110</nct_id>
  </id_info>
  <brief_title>Additional Effects of Perioperative Immunonutrition in Patients Undergoing Pancreaticoduodenectomy</brief_title>
  <official_title>Additional Effects of Perioperative Immunonutrition on Th1/Th2 Differentiation in Patients Undergoing Pancreaticoduodenectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chiba University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chiba University</source>
  <oversight_info>
    <authority>Japan: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate whether perioperative immunonutrition has
      additional effects on cell-mediated immunity in patients undergoing pancreaticoduodenectomy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators reported that perioperative immunonutrition had no additional effects
      compared with preoperative immunonutrition in patients underwent colorectal surgery (Braga
      M, Gianotti L, Vignali A, Carlo VD. Preoperative oral arginine and n-3 fatty acid
      supplementation improves the immunometabolic host response and outcome after colorectal
      resection for cancer. Surgery. 2002; 132:805-14, PMID: 12464864). Object of this study is to
      investigate the additional effects of perioperative immunonutrition on cell-mediated
      immunity and incidence of infectious complication after pancreaticoduodenectomy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">September 2015</completion_date>
  <primary_completion_date type="Anticipated">September 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>plasma resolvin E1, cell-mediated immunity</measure>
    <time_frame>30 days</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>infectious complication rate</measure>
    <time_frame>30 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Pancreatic Tumor</condition>
  <condition>Bile Duct Tumor</condition>
  <arm_group>
    <arm_group_label>Perioperative</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral IMPACT (1 L/day) for 5 days before surgery and by enteral feeding after surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Preoperative</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral IMPACT 1000ml/day for 5 days (1 L/day) before surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Oral IMPACT</intervention_name>
    <description>Oral IMPACT enriched with arginine, omega-3 fatty acids, and RNA by enteral feeding after surgery</description>
    <arm_group_label>Perioperative</arm_group_label>
    <arm_group_label>Preoperative</arm_group_label>
    <other_name>Oral IMPACT; Ajinomoto Pharma Co., Ltd, Tokyo, Japan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients undergoing pancreaticoduodenectomy

        Exclusion Criteria:

          -  age younger than 18 years old

          -  ongoing infection

          -  gastrointestinal obstruction

          -  respiratory dysfunction

          -  cardiac dysfunction

          -  hepatic dysfunction

          -  renal failure

          -  history of recent immunosuppressive or immunological disease

          -  preoperative evidence of widespread metastatic disease
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Katsunori Furukawa, MD</last_name>
    <role>Study Director</role>
    <affiliation>Chiba University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Katsunori Furukawa, MD</last_name>
    <phone>+81-43-222-7171</phone>
    <phone_ext>72235</phone_ext>
    <email>k-furukawa@umin.ac.jp</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Daisuke Suzuki, MD</last_name>
    <phone>+81-43-222-7171</phone>
    <phone_ext>72234</phone_ext>
    <email>d-suzuki@umin.ac.jp</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chiba University Hospital</name>
      <address>
        <city>Chiba</city>
        <zip>260-8670</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katsunori Furukawa, MD</last_name>
      <phone>+81-43-222-7171</phone>
      <phone_ext>72235</phone_ext>
      <email>k-furukawa@umin.ac.jp</email>
    </contact>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 24, 2013</lastchanged_date>
  <firstreceived_date>October 5, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chiba University</investigator_affiliation>
    <investigator_full_name>Katsunori Furukawa</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Immunonutrition</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bile Duct Neoplasms</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
